Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 14/20 | 0.62 |
| ▸ | ITGB7 | P26010 | 14/20 | 0.62 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235727 | 0.89 | ITGA4 (0.54) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL8282103 | 0.85 | ITGA4 (0.86) | ITGA4ITGB7ITGB1 | |
| SCHEMBL1824118 | 0.84 | ITGA4 (0.56) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL6235939 | 0.82 | ITGA4 (0.51) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL13513460 | 0.81 | ITGA4 (0.53) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL22996744 | 0.80 | ITGA4 (0.51) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL919680 | 0.80 | ITGA4 (0.54) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL4649226 | 0.80 | ITGA4 (0.54) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL5163463 | 0.79 | ITGA4 (0.55) | ITGA4ITGB7KLK5CTSSCTSK | |
| SCHEMBL15136783 | 0.79 | ITGA4 (0.55) | ITGA4ITGB7KLK5CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745454-B2 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20050085459-A1 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2005-04-21 | — | — | US | disclosed |
| US-6803370-B2 | COMPOUNDS FOR USE IN THE TREATMENT OF ASTHMA, ALZHEIMER'S, DIABETES, ATHEROSCLEROSIS, INFLAMMATORY BOWEL DISEASE, ARTHRITIS, TUMOR METASTASIS, ISCHEMIA AND BRAIN DISORDERS | ELAN PHARMACEUTICALS, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20020052470-A1 | Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2002-05-02 | — | — | US | disclosed |
| WO-2002008202-A2 | ALPHA AMINO ACID DERIVATIVES--INHIBITORS OF LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085459-A1 | Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ITGA4 6/4885ITGB7 148/4885KLK5 3545/4885 |
| US-20020052470-A1 | Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | ITGA4 7/4885ITGB7 158/4885KLK5 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.